Edgewise Therapeutics Inc

NASDAQ EWTX

Download Data

Edgewise Therapeutics Inc Quick Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Edgewise Therapeutics Inc Quick Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO Dr. Kevin Koch Ph.D.
IPO Date March 26, 2021
Location United States
Headquarters 3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees 92
Sector Healthcare
Industry Biotechnology
Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Similar companies

IPSC

Century Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

ACET

Adicet Bio Inc

NA

NA

VOR

Vor Biopharma Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email